Bimekizumab yields clinically meaningful improvements in the severity of hidradenitis suppurativa over 48 weeks, shifting most patients to a mild disease, a pooled analysis of two trials shows.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results